<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0204870.ref020">
 <label>20</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Younes</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Santoro</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Shipp</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Zinzani</surname>
   <given-names>PL</given-names>
  </name>, 
  <name>
   <surname>Timmerman</surname>
   <given-names>JM</given-names>
  </name>, 
  <name>
   <surname>Ansell</surname>
   <given-names>S</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial</article-title>. 
  <source>Lancet Oncol</source>. 
  <year>2016</year>;
  <volume>17</volume>(
  <issue>9</issue>):
  <fpage>1283</fpage>â€“
  <lpage>94</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S1470-2045(16)30167-X</pub-id> ; PubMed Central PMCID: PMCPMC5541855.
  <?supplied-pmid 27451390?>
  <pub-id pub-id-type="pmid">27451390</pub-id>
 </mixed-citation>
</ref>
